Search is Powered by Google
Cancer / Oncology News

Oncolin Therapeutics Announces Its Lead Technology Has Shown To Be Effective In Treating Cancer In Animal Models

Main Category: Cancer / Oncology
Also Included In: Neurology / Neuroscience
Article Date: 16 Apr 2008 - 4:00 PST

email icon email to a friend   printer icon printer friendly   write icon view / write opinions   rate icon rate article


Current Article Ratings:

Patient / Public:4 stars

4 (1 votes)

Health Professional:not yet rated

Article Opinions: 0 posts

Oncolin Therapeutics, Inc., (OTCBB:OCOL) (Oncolin) announces that one of its lead drug candidates has shown in preclinical testing that it extends the life of animals that have human tumors implanted in their brains. The early testing has yielded results in animals that are equivalent to that of Temodar®, which is one of the leading cancer treatments for brain cancer with annual revenues in excess of $500 million annually. This technology is covered under Oncolin's recent exclusive option to license from The University of Texas M.D. Anderson.

In further studies it was determined that the administration of a combination of our compound with Temodar® produces superior anti-tumor activity when compared to Temodar® alone, resulting in increased survival.

"Even though these tests are very early stage they have generated some very positive results which validate our theory of this treatment. We are continuing to undertake and complete the preclinical studies required for a goal of beginning a phase I trial by the beginning of 2009," said Dr. Donald Picker, President and COO.

Recent News

Oncolin Therapeutics Obtains an Exclusive Worldwide Right to Option Patents Covering the Composition and Use of Genistein Analogs for Cancer Treatment

Oncolin has recently announced that is has obtained an exclusive option agreement with the Pharmaceutical Research Institute of Warsaw, Poland, which provides the company the right to license the use of Genistein analogs for cancer treatment.

Oncolin Announces Its Research Program Receives Peer Reviewed National Institute of Health Grant of $179,000.

About Oncolin Therapeutics, Inc.

Headquartered in Houston, Texas, Oncolin Therapeutics, Inc. is a publicly traded biopharmaceutical company that engages in the discovery, development and commercialization of novel selective anticancer therapies. Additional information about Oncolin can be found on the web at http://www.oncolinthera.com.

Safe Harbor Statement

This press release contains statements that may constitute forward-looking statements, including the company's ability to successfully acquire and develop technologies that are and may be acquired. These statements are based on current expectations and assumptions and involve a number of uncertainties and risks that could cause actual results to differ materially from those currently expected. For additional information about Oncolin's future business and financial results, refer to Oncolin's Quarterly Report on Form 10-QSB for the quarter ended December 31, 2007 and Annual Report on Form 10-KSB for the year ended March 31, 2007. Oncolin Therapeutics undertakes no obligation to update any forward-looking statement that may be made from time to time by or on behalf of the company, whether as a result of new information, future events or otherwise.

Oncolin Therapeutics, Inc.

View drug information on Temodar.





Personalized Homepage Weekly Newsletters Daily News Alerts
Opioid Induced Constipation ADHD Anxiety Asthma Autism Cancer Diabetes Lung Cancer Lupus Medicare / Medicaid Obesity and BMI Pancreatic Cancer Stem Cells All 'What Is...' Articles All 'How To...' Articles

Ophthalmology Urology
About Us News Licensing Free Website Feeds Free Tools & Content Tell a Friend Accessibility Help / FAQ Article Submission Links Contact Us

add medical news today to your facebook
medical news gadget

Swine Flu Image

Swine Flu Updates

- Latest Swine Flu News
- What is Swine Flu?
- Map Of H1N1 Outbreaks
- Swine Flu - Top 20 FAQ
- Daily Email News Alerts
Stick with Medical News Today for the latest news updates on swine flu.


These are the most read articles from this news category for the last 6 months:
Top Article Star
Understanding And Treating Triple-Negative Breast Cancer
07 Jan 2009
Triple-negative breast cancer is a subtype of breast cancer that is clinically negative for expression of estrogen and progesterone receptors (ER/PR) and HER2 protein. It is characterized by its unique molecular profile...


Monitoring and Adherence in CML image Monitoring and Adherence in CML

Imatinib, or Gleevec, is a targeted anti-cancer drug that can keep chronic myelogenous leukemia (CML) in check for most patients for many years. It is important for patients to take imatinib as prescribed by their doctor to fight the disease and to guard against resistance...

Treating HER2+ Breast Cancer image Treating HER2+ Breast Cancer

There are at least four different kinds of breast cancer and each is treated differently. For HER2+ breast cancer, a chemotherapy drug is typically the best option. Here's an overview of the drugs used to treat breast cancer...

View more videos...